LC/MS/MS of Digoxin and Digitoxin in Serum or Plasma on Titan™ C18 after SPE with HybridSPE®-Phospholipid, Minimization of Matrix Effects

LC/MS/MS of Digoxin and Digitoxin in Serum or Plasma on Titan™ C18 after SPE with HybridSPE®-Phospholipid, Minimization of Matrix Effects

Conditions

sample preparation SPE (Solid Phase Extraction)
sample/matrix rat plasma or human serum spiked at 0.05 ng/mL with digitoxin and digoxin
SPE well plate HybridSPE-PLus 96-well Plate, 50 mg/well (575659-U)
sample addition 100 µl spiked rat plasma followed by 300 µl 1% formic acid in acetonitrile
elution apply vacuum
column Titan C18, 10 cm x 2.1 mm I.D., 1.9 µm particles (577124-U)
mobile phase 10 mM ammonium formate in methanol:water (80:20)
flow rate 0.2 ml/min
pressure 4550 psi (314 bar)
sample 0.05 ng/mL
injection 2 µl
detector ESI-MS/MS
detector MRM Transitions: Peak MRM(m/z) (1.) Digoxin 798.5/651.5 (2.) Digitoxin 782.5/635.5 or 243.2

Description

Analysis Note The cardiac glycosides digitoxin and digoxin are widely prescribed for treating congestive heart failure. There is a need for siµltaneous and sensitive determination of digitoxin and digoxin in biological fluids using LC/MS. This chromatogram shows the compounds at very low level of 0.05 ng/mL on a Titan C18 UHPLC column. The highest grade solvents provided clean, robust operation. Cerilliant CRMs and USP Reference Standards provided reliable quantification.
Categories Analytical Chromatography, SPE Applications, Clinical, cardiac drugs, Cardiac Drugs, Cardiac drugs
Featured Industry Clinical
Legal Information HybridSPE is a registered trademark of Sigma-Aldrich Co. LLC, Titan is a trademark of Sigma-Aldrich Co. LLC
suitability application for LC-MS, application for SPE

Materials

     
Related Links